Cite
HARVARD Citation
Hou, J. et al. (n.d.). P750 Biosimilar Infliximab Switching is Not Associated with Adverse Outcomes: A Real-World Effectiveness Analyses in a National U.S. Cohort of U.S. Military Veterans with Inflammatory Bowel Disease. Journal of Crohn's and colitis. pp. i880-i881. [Online].